Lindenhurst, IL, United States of America

Gregory A Gfesser

USPTO Granted Patents = 37 (Patent Applications = 8)

CIPO Patents = 6 (Patent Applications = 12)

EPO Patents = 9 (Patent Applications = 17)

Average Co-Inventor Count = 10.3

ph-index = 6

Forward Citations = 123(Granted Patents)

Location History:

Waukegan, IL (US) (2005 - 2009)
Lindenhurst, IL (US) (2006 - 2021)

Company Filing History:

Abbott Laboratories Corporation

where one patent can have more than one assignee

Years Active: 2005-2021

Loading Chart...

37 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10988454 - Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use (2021-04-27),

2. 10981890 - Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use (2021-04-20),

3. 10844042 - Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use (2020-11-24),

4. 10844041 - Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use (2020-11-24),

5. 10829473 - Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use (2020-11-10),

6. 10647717 - N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2020-05-12),

7. 10428017 - Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use (2019-10-01),

8. 10399940 - Substituted pyrrolidines and methods of use (2019-09-03),

9. 10259810 - N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2019-04-16),

10. 10130622 - Compounds for treatment of cystic fibrosis (2018-11-20),

11. 10047051 - Substituted pyridines and method of use (2018-08-14),

12. 9983218 - Indole and indoline derivatives and methods of use thereof (2018-05-29),

13. 9981910 - Substituted pyrrolidines and methods of use (2018-05-29),

14. 9890158 - N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2018-02-13),

15. 9840513 - Substituted tricyclics and method of use (2017-12-12),

Title: Gregory A Gfesser: Pioneering Tech Inventor Shaping Tomorrow's World

Introduction: Gregory A Gfesser, a resident of Lindenhurst, IL, USA, is a visionary inventor whose passion for innovation and relentless pursuit of excellence have solidified his position as a pioneering figure in the tech industry. With 37 patents to his name, Gfesser continues to inspire future generations of inventors to think innovatively and craft solutions that can shape the world of tomorrow.

Latest Patents: Among his latest patents is the groundbreaking work on "Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use." This invention unveils compounds of Formula (I) aimed at treating cystic fibrosis, highlighting his commitment to addressing significant medical challenges through inventive solutions.

Career Highlights: Gfesser has made significant contributions during his tenure at reputable companies such as Galapagos NV and AbbVie Inc., where his innovative mindset and dedication to excellence have undoubtedly left a lasting impact. His collaborative efforts within these organizations have led to remarkable advancements in the field of technology and healthcare.

Collaborations: Throughout his career, Gfesser has worked alongside esteemed colleagues such as Philip R Kym and Robert J Altenbach. Together, they have synergized their expertise and creativity to drive innovation, resulting in the development of pioneering technologies that have garnered recognition within the industry.

Conclusion: Gregory A Gfesser's remarkable journey as a tech inventor serves as a testament to the transformative power of innovation. His unwavering commitment to pushing boundaries and creating impactful solutions underscores his legacy as a trailblazer in the world of technology. Gfesser's influence continues to resonate across generations, inspiring aspiring inventors to embrace creativity, challenge conventions, and shape a brighter future through innovation.

This text is generated by artificial intelligence and may not be accurate.